Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
about
Direct-acting antivirals for the treatment of chronic hepatitis C: open issues and future perspectivesRole of Marine Natural Products in the Genesis of Antiviral AgentsNew era for management of chronic hepatitis C virus using direct antiviral agents: A reviewHCV Kinetic Models and Their Implications in Drug DevelopmentFinally sofosbuvir: an oral anti-HCV drug with wide performance capabilityChronic hepatitis C: future treatmentOral antiviral therapies for chronic hepatitis C infectionAntiviral treatment of hepatitis C virus infection and factors affecting efficacyModelling hepatitis C therapy--predicting effects of treatmentEmerging therapies for the treatment of hepatitis CDiscovery of N -[4-[6- tert -Butyl-5-methoxy-8-(6-methoxy-2-oxo-1 H -pyridin-3-yl)-3-quinolyl]phenyl]methanesulfonamide (RG7109), a Potent Inhibitor of the Hepatitis C Virus NS5B PolymeraseChimeric mouse model for the infection of hepatitis B and C virusesAdvances in the treatment of hepatitis C virus infectionTreatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modellingSafety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients.Frontiers in the treatment of hepatitis C virus infection.Direct-acting antiviral agents and the path to interferon independence.Current and future therapies for hepatitis C virus infection.Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study.Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more.MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.Direct-acting antiviral agents for hepatitis C virus infection.Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale modelInvestigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus.Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise reviewComparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Direct-acting antivirals for chronic hepatitis C.Interferon in the treatment of chronic hepatitis C: a drug caught between past and future.Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosisSecond-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration.Danoprevir monotherapy decreases inflammatory markers in patients with chronic hepatitis C virus infection.Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C.A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV.New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy.Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution.The treatment response of chronically hepatitis C virus-infected patients depends on interferon concentration but not on interferon gene expression in peripheral blood mononuclear cells.Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128)Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection.Treating hepatitis C infection by targeting the host.
P2860
Q21265028-D20FCC1A-1C3B-40F7-84DB-50A74E866702Q26796360-34DC8DBE-A9E2-4185-A054-F586C102382DQ26800050-2206586F-9E61-4E7E-BF0A-33FC44DF9A55Q26801602-244965C8-0A9E-4488-A2A4-1C68144DB791Q26822400-629BFF0B-67D4-40B4-B407-8384DE5812CDQ26824075-B03A7D9C-9618-4551-9F5E-B624E5789A57Q26830426-97F71332-D801-486A-8365-A8FD8D13DC72Q26851810-75988964-F5C3-4D50-846C-05574868DD95Q26864673-4B3F6C99-12D5-4A6A-B7F1-A95F126D1184Q27003319-2F52298F-4720-4C65-A5A6-2C43EE89E5D5Q27680539-E365034C-02D7-46D6-BB7C-0CB70564E457Q28534370-812D7A4D-3F1C-4D52-97CC-C457346F6C70Q30415138-3B7245B4-4175-4B86-B37C-D6FF53FBD093Q30583856-D19B2AA1-25F6-4135-99DA-677575CC00B5Q33401381-44864740-C2DF-47A8-817D-1FCF85F28607Q33571517-464A943F-B5AB-4824-BBD7-293233E08312Q33727347-8DC39B59-076D-492C-B018-10BADE6079C0Q34036762-E851E7DD-029F-48EC-993A-035F1247A8A3Q34040906-42520828-4E96-495A-B06D-C64D364BCEC3Q34172595-DA38A264-097C-412F-ADFD-9D98E1A99FA6Q34276394-0E63BC89-FC3D-4A7C-AA09-F4D262F5D864Q34321440-12B26558-A2DB-4956-AAC6-FCED00EDDBBAQ34334375-347BE8E6-4A6A-43B3-BA58-BD6FDC9C3F02Q34420891-08E03800-276F-40CB-854E-464F1F15270AQ34439125-A473A497-E94A-4722-9D05-1D1E2CC9C0E5Q34489239-6E68762F-C55B-41A9-88BB-69C74C00374EQ34557595-4F7FF482-2625-44F5-95C1-899BE5EE88EBQ34626479-C51207B4-3314-4C50-BF5E-60E5F846E525Q34926607-9A84C18F-CD0F-42E6-87FB-0B7189CDDD1CQ35012057-A58D3E39-4174-4225-8C49-06396BBBEFB5Q35065912-AFCBDD5C-4EA0-4A9B-A250-A8AD4C3E9023Q35135565-FFD62151-DE38-4A33-96BA-1CBA2F2972D4Q35449696-60BA101E-EC2F-45DC-BB58-B3194A5BDC61Q35653358-956E1A03-0701-40F1-9AE4-88466BE99623Q35666393-FF15DB26-717D-41B7-ADF9-615A7319C35CQ35689238-9DF26599-1772-4E28-8B92-29C98224FF42Q35867385-A12E354C-8CD0-48D8-B2B7-6C6708C2C2F4Q35878898-2C7CEC82-485F-428D-A88A-32E4961FCBA6Q35905985-9077DAF2-5F59-46C3-91C1-66D7D70A8E49Q35992555-7DA866B2-B250-4CC3-A5D6-EB92E299C7D2
P2860
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Oral combination therapy with ...... rolled, dose-escalation trial.
@en
Oral combination therapy with ...... rolled, dose-escalation trial.
@nl
type
label
Oral combination therapy with ...... rolled, dose-escalation trial.
@en
Oral combination therapy with ...... rolled, dose-escalation trial.
@nl
prefLabel
Oral combination therapy with ...... rolled, dose-escalation trial.
@en
Oral combination therapy with ...... rolled, dose-escalation trial.
@nl
P2093
P1433
P1476
Oral combination therapy with ...... rolled, dose-escalation trial.
@en
P2093
Brett Ritchie
Catherine A M Stedman
Edward J Gane
Isabel Najera
Linda Baher
M Michelle Berrey
Mark Laughlin
Nancy S Shulman
Patrick F Smith
P304
P356
10.1016/S0140-6736(10)61384-0
P407
P577
2010-10-14T00:00:00Z